TELA Bio Stock (NASDAQ:TELA)
Previous Close
$2.80
52W Range
$2.30 - $7.84
50D Avg
$2.84
200D Avg
$4.04
Market Cap
$112.16M
Avg Vol (3M)
$211.74K
Beta
0.97
Div Yield
-
TELA Company Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FNA | Paragon 28, Inc. |
| OFIX | Orthofix Medical Inc. |
| LUNG | Pulmonx Corporation |
| NPCE | NeuroPace, Inc. |
| KIDS | OrthoPediatrics Corp. |
| TMDX | TransMedics Group, Inc. |
| SGHT | Sight Sciences, Inc. |
| VREX | Varex Imaging Corporation |
| DCTH | Delcath Systems, Inc. |
| CLPT | ClearPoint Neuro, Inc. |
| AXGN | AxoGen, Inc. |
| SIBN | SI-BONE, Inc. |
| TCMD | Tactile Systems Technology, Inc. |
| CVRX | CVRx, Inc. |
| RXST | RxSight, Inc. |